Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 16 of 16 publications.

Mangel AW, Johanson JF, Li YP, Kersey K, Daniels O. Defining a responder in treatment trials for chronic idiopathic constipation: authors' reply. Aliment Pharmacol Ther. 2011 Jan 15;33(2):286-7.

Goldberg M, Li Y-P, Johanson JF, Mangel AW, Kitt M, Beattie DT, Kersey K, Daniels O. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4-week, randomized, double-blind, placebo-controlled, dose–response study. Aliment Pharmacol Ther. 2010 Nov 1;32(9):1102-12.

Mangel AW, Bornstein JD, Hamm LR, Buda JJ, Wang J, Irish W, Urso D. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2008 Jul 1;28(2):239-49.

Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, Mangel AW, Fehnel SE. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008 Jun 15;27(12):1224-32.

Leventer SM, Raudibaugh K, Frissora CL, Kassem N, Keogh JC, Phillips J, Mangel AW. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant. Aliment Pharmacol Ther. 2008 Jan;27(2):197-206.

Williams RE, Black CL, Kim HY, Andrews EB, Mangel AW, Buda JJ, Cook SF. Determinants of healthcare-seeking behaviour among subjects with irritable bowel syndrome. Aliment Pharmacol Ther. 2006 Jun 1;23(11):1667-75.

Mangel AW. Personal view: adequate relief as a primary endpoint in irritable bowel syndrome. Aliment Pharmacol Ther. 2006 Apr 1;23(7):879-81.

Williams R, Black C, Kim H, Andrews EB, Mangel AW, Buda JJ, Cook SF. Stability of irritable bowel syndrome using a Rome II-based classification. Aliment Pharmacol Ther. 2006 Jan 1;23(1):197-205.

Mangel AW, Fehnel SE. Global endpoints in functional gastrointestinal disease. Aliment Pharmacol Ther. 2005 Dec 1;22(11-12):1162-3.

Andrews EB, Eaton SC, Hollis KA, Hopkins JS, Ameen VZ, Hamm LR, Mangel AW, Tennis P, Cook SF. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther. 2005 Nov 10;22:935-42.

Mangel AW. Study design issues in irritable bowel syndrome. Aliment Pharmacol Ther. 2004 Jan 1;19(1):141-2.

Talley NJ, Van Zanten SV, Saez LR, Dukes G, Perschy T, Heath M, Kleoudis C, Mangel AW. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther. 2001 Apr 1;15(4):525-37.

Camilleri M, Mayer EA, Drossman DA, Heath AT, Dukes GE, McSorley DJ, Kong S, Mangel AW, Northcutt AR. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999 Sep;13(9):1149-59.

Mangel AW, Northcutt AR. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients. Aliment Pharmacol Ther. 1999 May 1;13(Suppl 2):77-82.

Pappas TN, Mangel AW, Lawson C. Alosetron: central and peripheral effects in an animal model of gut distension. Aliment Pharmacol Ther. 1999;13(Suppl 2):54-6.

Harding JP, Hamm LR, Ehsanullah RS, Heath AT, Sorrells SC, Haw J, Dukes GE, Wolfe SG, Mangel AW, Northcutt AR. Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome. Aliment Pharmacol Ther. 1997 Dec 1;11(6):1073-6.